Acrivon Therapeutics (ACRV)

• Market cap: $75.8M
• 1 day: 2.91%
• 5 days: 2.31%
• 1 month: -10.61%
• 3 months: -7.81%
• 6 months: 8.59%
• Year to date: -28.05%
• 1 year: 35.11%
• 5 years: -89.36%
• 10 years: -89.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Employees: 76